Clinical trial
A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
NCT02418767 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
- Lead sponsor
- OPKO Health, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- June 30, 2015
- Enrollment
- 42 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
growth hormone deficiency